Usage: INVEGA SUSTENNA (paliperidone palmitate) is indicated for the treatment of schizophrenia and schizoaffective disorder in adults, both as monotherapy and as an adjunct to mood stabilizers or antidepressants.
Usage: INVOKAMET and INVOKAMET XR are indicated as adjuncts to diet and exercise for improving glycemic control in adults and pediatric patients aged 10 and older with type 2 diabetes mellitus. Canagliflozin component reduces risks of major cardiovascular events and kidney disease in specific patient populations.
Usage: INVOKANA (canagliflozin) is indicated as an adjunct to diet and exercise for improving glycemic control in adults and pediatric patients with type 2 diabetes. It reduces risks of major cardiovascular events and end-stage kidney disease in adults with type 2 diabetes and specific health complications. Usage in type 1 diabetes or severe renal impairment is not recommended.
Usage: PONVORY is indicated for treating relapsing forms of multiple sclerosis (MS) in adults, including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease.
Usage: RISPERDAL (risperidone) is indicated for the treatment of schizophrenia, acute manic or mixed episodes of Bipolar I Disorder (as monotherapy or adjunctive therapy), and irritability associated with autistic disorder in children and adolescents. Efficacy is supported by multiple clinical trials in various age groups.